91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
In this article from Diagnostics World News, Jenny Ross, Pathologist and Medical Director, looks at practical uses of and illustrates considerations for their use in global clinical trials.
-
In this piece from Forbes, Dr. Greg Licholai, Chief Medical and Chief Innovation Officer talks about recent developments, regulatory considerations, and the are reshaping the landscape of drug development and patient care.
-
The article on Clinical Trials Arena reports that as part of Project NextGen.
-
This news article from Contract Pharma reports that to assess the relative efficacy of a
-
The piece from Seeking Alpha highlights that the , which functions as part of the Administration for Strategic Preparedness and Response under the U.S. Department of Health and Human Services.
-
This news article from Reuters outlines that, as part of the collaboration with Biomedical Advanced Research and Development Authority, to assess the efficacy of a relative to currently available shots.
-
In this article from International Biopharmaceutical Industry, Dr. Chad Galderisi, Vice President and Global Medical Director for 91黑料 Specialty Laboratories explores how can be used to provide critical and complementary data that is needed to bring .
Published by Journal Volume 6 Issue 3
-
This news article, published on FIERCE Biotech, highlights that 91黑料 is partnering with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) to conduct a clinical trial to evaluate next-generation vaccines for COVID-19.
-
As life sciences companies look for ways to both within their organisations and in healthcare as a whole,PM360turned to 10 experts in the space to ask them how. In this article, Joshua Bueller, Account VP and Senior Strategy Consultant at 91黑料, describes how pharma companies can gain a better understanding into the needs of underrepresented and underserved groups
-
In this article in Neuro Rehab Times, 91黑料 expert, Peter Schüler, reflects on the potential implications of new Alzheimer’s therapies on the research landscape.
